Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

British Journal of Cancer

Volumn 77, Issue 9, 1998, Pages 1405-1412

  Adams, G P ^a   Schier, R ^b   McCall, A M ^a   Crawford, R S ^b   Wolf, E J ^a   Weiner, L M ^a   Marks, J D ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Avidity; Diabody; Immunodeficient mice; Single chain Fv; Tumour targeting

Indexed keywords

BISPECIFIC ANTIBODY; CANCER ANTIBODY;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER IMMUNOTHERAPY; DRUG RETENTION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR;

EID: 0031942906     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.233     Document Type: Article

References (50)

1. Adams GP, DeNardo SJ, Amin A, Kroger LA, DeNardo GL, Hellström I and Hellström KE (1992) Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric Ch-L6 antibody. Antibody Immunoconj Radiopharmaceut 5: 81-95
2. Adams GP, McCartney JE, Tai M-S, Oppermann H, Huston JS, Stafford WF, Bookman MA, Fand I, Houston LL and Weiner LM (1993) Highly specific in vivo tumour targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53: 4026-4034
3. Adams GP, McCartney JE, Wolf EJ, Tai M-S, Schier R, Stafford WF, Marks JD, Bookman MA, Huston JS and Weiner LM (1996). Influence of avidity on the tumor retention of monospecific and hispecific anti-c-erbB-2 single-chain Fv dimers. Proc Am Assoc Cancer Res 37: 472
4. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC and McGuire WL (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23: 974-979
5. Beaumier PL, Krohn KA, Carrasquillo JA, Eary J, Hellström I, Hellström KE, Nelp WB and Larson SM (1985) Melanoma localization in nude mice with monoclonal Fab against p97. J Nucl Med 26: 1172-1179
6. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ and Robson L (1996) Clinical evidence of efficient tumor targeting based upon single-chain Fv antibody selected from a combinatorial library. Nature Med 2: 979-984
7. Bentel GC, Nelson CE and Noell KT (1989) Treatment Planning and Dose Calculation in Radiation Oncology, Pergamon Press: New York
8. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL and Marks P (1990) Overexpression of HER2/neu is asociated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091
9. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS and Whitlow M (1988) Single-chain antigen-binding proteins. Science 242: 423-426
10. Breitling SD, Seehaus T, Klewinghaus I and Little M (1991) A surface expression vector for antibody screening. Gene 104: 147-153
11. Colcher DR, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE and Schlom J (1990) In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82: 1191-1197
12. Earp HS, Dawson TL, Li X and Yu H (1995) Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35: 115-132
13. Ferencik M (1993) The Immunoglobulins. In Handbook of Immunology, pp. 69-109. Chapman & Hall: London
14. Fujimori K, Covell DG, Fletcher JE and Weinstein JN (1989) Modeling analysis of the global and microscopic distribution of immunoglobulin G. F(ab′)2 and Fab in tumors. Cancer Res 49: 5656-5663
15. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP and Shawver LK (1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-Diamminedichlorplatinum against human breast and ovarian tumor cell lines. Cancer Res 51: 4575-4580
16. Hochuli E, Bannwarth W, Dobeli H, Gentz R and Stuber D (1988) Genetic approach to facilitate purification of recombinant proteins with a novel metal chelate. Bio/Technology 6: 1321-1325
17. Holliger P, Prospero T and Winter G (1993) 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90: 6444-6448
18. Hu Shi-zhen SL, Raubitschek A, Sherman M, Williams LE, Wong JYC, Shively JE and Wu AM (1996) Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56: 3055-3061
19. Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S and Novotny J (1988) Protein engineering of antibody binding sites: recovery of specific activity in an antidigoxin single-chain Fv analogue produced in E coli. Proc Natl Acad Sci USA 85: 5879-5883
20. Huston JS, George AJT, Adams GP, Stafford WF, Jamar F, Tai M-S, McCartney JE, Oppermann H, Heelan BT, Peters AM, Houston LL, Bookman MA, Wolf EJ and Weiner LM (1996) Single-chain Fv radioimmunotargeting. Q J Nucl Med 40: 320-333
21. Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50: (suppl.) 814s-819s
22. Jønsson U, Faegerstam L, Ivarsson B, Lundh K, Løfås S, Persson B, Roos H, Rønnberg I, Sjølander S, Stenberg E, Ståhlberg R, Urbaniczky C, Østlin H and Malmqvist M (1991) Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Bio Techniques 11: 620-627
23. Juweid MN, R Paik, Perez-Bacete C, M Sato, J van Osdol W and Weinstein JN (1992) Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for binding site barrier. Cancer Res 52: 5144-5153
24. Kaminski MS, Zasady KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD and Wahl RL (1993) Radioimmunotherapy of B-cell lymphoma with 131I-anti-B1 (anti-CD20) antibody. New Engl J Med 329: 459-465
25. Karlson RA, Michaelsson A and Mattsson L (1991) Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methodol 145: 229-240
26. King CR, Kraus MH and Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974-976
27. Kraus MH, Popeseu NC, Amsbaugh SC and King CR (1987) Overexpression of the EGF receptor-related proto-oncogene erhB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6: 605-610
28. Laub P and Gallo J (1996) NCOMP - a windows-based computer program for noncompartmental analysis of pharmacokinetic data. J Pharmaceut Sci 85: 393-395
29. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD and Winter G (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222: 581-597
30. McCartney JE, Tai M-S, Hudziak RM, Adams GP, Weiner LM, Jin DJ, Stafford III WF, Liu S, Bookman MA, Laminet AA, Fand I, Houston LL, Oppermann H and Huston JS (1994). Engineering disulfide-linked single-chain Fv dimers [(sFv′)2] with improved solution and targeting properties: antidigoxin 26-10 (sFv′)2 and anti-c-erbB-2 741F8 (sFv′)2 made by protein folding and bonded through C-terminal cysteinyl peptides. Protein Engineering 18: 301-314
31. Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, Wood JF, Whitlow M, Snoy P and Schlom J (1991) Construction, binding properties, metabolism, and targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51: 6363-6371
32. Molthoff CFM, Pinedo HM, Schlupper HMM, Nijman HW and Boven E (1992) Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibody OC125, OV-TL3 and 139H2 as IgG and F(ab′)2 fragments in experimental ovarian cancer. Br J Cancer 65: 677-683
33. Pack PK, M Schroeckh V, Knüpfer U, Wenderoth R, Riesenberg D and Plückthun A (1993) Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. BIO/Technology 11: 1271-1277
34. Pack PPA (1992) Miniantibodies: use of amphipathic helices to produce functional, flexably linked dimeric Fv fragments with high avidity in Escherichia coli. Biochemistry 31: 1579-1584
35. Perisic O, Webb PA, Hollinger P, Winter G and Williams RL (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2: 1217-1226
36. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fischer LD and Bernstein ID (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New Engl J Med 329: 1219-1224
37. Schier R, Marks JD, Wolf E, Apell G, Wong C, McCartney J, Bookman M, Huston J, Weiner L and Adams GP (1995) In vitro and in vivo characterization of a human anti-c-erbB2 single chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1: 73-81
38. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C and Marks JD (1996) Isolation of picomolar affinity anti-c-erhB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 263: 551-567
39. Siegel JA, Wessels BW, Watson EE, Stobin MG, Vriesendorp HM, Bradley EW, Badger CC, Brill AB, Kwok CS, Stickney DR, Eckerman KF, Fisher DR, Buchsbaum DJ and Order SE (1990) Bone marrow dosimetry and toxicity for radioimmunotherapy, Antibody Immunoconj Radiopharmaceut 3: 213-233
40. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
41. 131I-labeled monoclonal antibody RS7-3G11. Antibody Immunoconj Immunopharmaceut 4: 703-712
42. Stein R, Blumenthal R, Sharkey RM and Goldenberg DM (1994) Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab′)2 in nude mice bearing human tumor xenografts. Cancer 73: 816-823
43. van de Vijver M, van de Bersselaar R, Devilec P, Cornelisse C, Peterse J and Nusse R (1987) Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 7: 2019-2023
44. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W and Ullrich, A (1995) Heregulin-dependent regulation of HER2./neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267-4275
45. Ward ES, Gussow D, Griffiths AD, Jones PT and Winter G (1998) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341: 544-546
46. Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB and Alpaugh RK (1993) Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol 151: 2877-2887
47. Weiner LM, Houston LL, Huston JS, McCartney JE, Tai M-S, Apell G, Stafford WF, Bookman MA, Gallo JM and Adams GP (1995) Improving the tumor-selective delivery of single-chain Fv molecules. Tumor Targeting 1: 51-60
48. Wolf EA, Schreiber GJ, Cosand WL and Raff HV (1993) Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res 53: 2560-2565
49. Yokota T, Yamamoto T, Miyajima N, Toyoshima K, Nomuru N, Sakamoto H, Yoshida T, Terada M and Sugimura T (1988) Genetic alterations of the c-erbB2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2: 283-287
50. Yorke ED, Beaumier PL, Wessels BW, Fritzberg AR and Morgan C (1991) Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based upon mouse pharmacokinetics. Nucl Med Biol Int J Radiat Appl Instrum Part B 18: 827-835